Is Cumberland Pharmaceuticals Inc. (CPIX) a Sell? The Stock Formed Bearish Double Bottom Chart Pattern

July 27, 2018 - By Matthew Richard

Investors sentiment decreased to 0.69 in 2018 Q1. Its down 0.17, from 0.86 in 2017Q4. It dropped, as 4 investors sold Cumberland Pharmaceuticals Inc. shares while 9 reduced holdings. 1 funds opened positions while 8 raised stakes. 4.09 million shares or 0.64% less from 4.12 million shares in 2017Q4 were reported.
Savings Bank Of New York Mellon invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Morgan Stanley owns 20,415 shares or 0% of their US portfolio. Delta Asset Management Limited Co Tn holds 11,000 shares or 0.01% of its portfolio. California Pub Employees Retirement System, California-based fund reported 53,800 shares. 48,610 are held by Geode Capital. Tower Rech Capital Limited Co (Trc) has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Dimensional Fund Lp stated it has 883,085 shares. State Street Corp holds 0% or 11,258 shares. Jw Asset Mgmt Ltd Co accumulated 178,942 shares or 1.18% of the stock. Ariel Lc reported 1.01M shares. Cambridge Inv Research reported 10,000 shares. 23,723 were accumulated by Northern Tru. Bridgeway Capital Mngmt Incorporated accumulated 283,700 shares. State Common Retirement Fund holds 260,730 shares or 0% of its portfolio. Blackrock Inc reported 332,482 shares.

Since March 19, 2018, it had 2 buys, and 0 sales for $4,464 activity.

The chart of Cumberland Pharmaceuticals Inc. (CPIX) shows a double bottom with $5.89 target or 3.00 % below today’s $6.07 share price. The 8 months chart pattern indicates high risk for the $95.37 million company. It was reported on Jul, 27 by If the $5.89 price target is reached, the company will be worth $2.86M less. Double bottoms are rare but powerful chart patterns.

The stock increased 0.83% or $0.05 during the last trading session, reaching $6.07. About 12,083 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 14.79% since July 27, 2017 and is downtrending. It has underperformed by 27.36% the S&P500.

Analysts await Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report earnings on August, 14. They expect $-0.08 EPS, down 14.29 % or $0.01 from last year’s $-0.07 per share. After $-0.11 actual EPS reported by Cumberland Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Ratings Coverage

Among 2 analysts covering Cumberland (NASDAQ:CPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cumberland had 2 analyst reports since April 17, 2018 according to SRatingsIntel. FBR Capital initiated the stock with “Buy” rating in Tuesday, April 17 report.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. The company has market cap of $95.37 million. The Company’s marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.